$Fulcrum Therapeutics (FULC.US)$ NEWS Fulcrum Therapeutics A...
NEWS
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
Fulcrum Therapeutics, a biopharmaceutical company, published Phase 2b clinical trial results of losmapimod for FSHD in The Lancet Neurology. While not meeting the primary endpoint, losmapimod showed improvements in structural and functional outcomes, with Phase 3 data expected in Q4 2024.
Positive
Improvements in structural and functional outcomes observed with losmapimod treatment
Positive patient-reported global impression of change compared to placebo
Losmapimod well tolerated with no serious adverse events reported
Completion of enrollment for Phase 3 clinical trial with topline data expected in Q4 2024
Negative
Primary endpoint of change in DUX4-driven gene expression did not show significant differences between treatment and placebo groups
Positive
Improvements in structural and functional outcomes observed with losmapimod treatment
Positive patient-reported global impression of change compared to placebo
Losmapimod well tolerated with no serious adverse events reported
Completion of enrollment for Phase 3 clinical trial with topline data expected in Q4 2024
Negative
Primary endpoint of change in DUX4-driven gene expression did not show significant differences between treatment and placebo groups
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
664Followers
75Following
4217Visitors
Follow